Who
Renee P. Tannenbaum
Director
Company insider
Files Form 4 as: Director, Cardiff Oncology; Director, ANI Pharmaceuticals; Director, Zogenix; Director, Sharps Compliance.
In numbers
- Trades disclosed
- 47
- Buys
- 6
- Sells
- 5
- Bought
- $307K
- Sold
- $1.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 16 Mar 2012
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 21 May 2026filed 10 Jun 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,357 at $0.00 | filing |
| 21 May 2026filed 10 Jun 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,357 at $0.00 | filing |
| 5 Dec 2025filed 9 Dec 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $146K1,800 at $81.15 | filing |
| 26 Jun 2025filed 30 Jun 2025 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,336 at $0.00 | filing |
| 12 Dec 2024filed 16 Dec 2024 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $34K10,000 at $3.42 | filing |
| 27 Jun 2024filed 1 Jul 2024 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,700 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,410 at $0.00 | filing |
| 16 May 2024filed 17 May 2024 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $128K2,000 at $63.87 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,700 at $0.00 | filing |
| 23 May 2023filed 24 May 2023 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,865 at $0.00 | filing |
| 15 Sep 2022filed 19 Sep 2022 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $11K6,400 at $1.72 | filing |
| 15 Sep 2022filed 19 Sep 2022 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $6,1923,600 at $1.72 | filing |
| 19 Mar 2022filed 22 Mar 2022 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —13,346 at $0.00 | filing |
| 9 Mar 2022filed 10 Mar 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,800 at $0.00 | filing |
| 7 Mar 2022filed 9 Mar 2022 | Zogenixoption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 7 Mar 2022filed 9 Mar 2022 | Zogenixoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 7 Mar 2022filed 9 Mar 2022 | Zogenix | SEC FORM 4 Code U | —32,567 | filing |
News
No headline names them, or the companies they trade most, lately.